Particle Sciences, Inc (PSI), the leading CDMO for micro and nano-particulates is expanding its sterile and aseptic manufacturing capacity generally and specifically for nano-milled drug products.
According to Mark Mitchnick, CEO at Particle Sciences, "In 2014 we initiated a record number of projects that are headed into the clinic with over 50% of those being sterile and 50% of those requiring aseptic processing. Several years ago, most of clinic bound work was developed at PSI but we have seen a significant uptick in projects that were developed at our clients’ facilities and are now being transferred to us for manufacturing. This is especially true with some of our larger multinational clients." Particle Sciences’ cGMP facilities include dedicated high potency suites, ISO 5 areas, six ISO 7/8 suites, attached warehouse, lyophilization, and full stability and analytic support. Mitchnick added, "We are incorporating a great deal of flexibility into this latest expansion by making intelligent use of both fixed and mobile isolator assets and coupling that with our existing ICH compliant stability programs and GMP analytic services group. Of course, our formulation expertise remains at the core of our activities. Being uniquely capable of bringing complex projects from concept through to manufacturing meets a real need and offers a compelling value proposition to our clients. Last year we grew by 16% and expect positive things in 2015 as well.
Particle Sciences is an integrated provider of drug development services. Particle Sciences works with BCS II/III/IV molecules, biologics and highly potent compounds using a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email [email protected] or contact us at (610) 861- 4701 for information.
Canada’s proactive policies reduce drug shortages far more effectively than the U.S.